Variations in the Management of Canadian Patients With CFTR Related Metabolic Syndrome/Cystic Fibrosis Screen Positive, Inconclusive Diagnosis (CRMS/CFSPID)
Pediatric Pulmonology · 2025
DOI: 10.1002/ppul.71200 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pediatric Pulmonology, 2025. Verfasst von Dana Chemali und 4 weiteren Autor:innen. Beteiligte Einrichtung: Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada. Hauptthemen laut MEDLINE: Cystic Fibrosis, Cystic Fibrosis Transmembrane Conductance Regulator, Metabolic Syndrome. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: The authors received no specific funding for this work..
Abstract (Originalsprache)
Background
With routine newborn screening for cystic fibrosis (CF) now considered standard of care, the designation of CFTR Related Metabolic Syndrome (CRMS) or CF screen positive, indeterminate diagnosis (CFSPID) has been established. The majority of CRMS/CFSPID patients remain asymptomatic; however, 3.8%–44% of these patients may progress to a diagnosis of CF. This raises the question of how to optimally manage CRMS/CFSPID patients. We set out to gain a better understanding of the past practices employed at CF centers across Canada in the care of patients with a diagnosis of CRMS/CFSPID.
Methods
An invitation to participate in an online survey was disseminated to CF centers in Canada through the REDCap database. The survey was completed in 2018. It included questions addressing patient population, timing of follow‐up of CRMS/CFSPID patients, and details around specific investigations ordered.
Results
Twelve out of 20 qualifying clinics completed the survey. The total patient population compiled included 1412 patients, of which 171 (12%) were classified as CRMS/CFSPID. There was wide variability in the timing of follow‐up with a median (IQR) of 6 (5.25–12) months and a range of 3–12 months. There was also wide variability in the timing of repeat investigations such as sweat chloride, respiratory cultures, chest x ‐rays and spirometry.
Conclusions
With current evidence showing that a considerable number of CRMS/CFSPID patients may progress to CF, ensuring these patients are identified as early as possible and followed in a consistent manner is essential. The Cystic Fibrosis Foundation and European Cystic Fibrosis Society have recently developed guidelines regarding the care of these patients. This survey describes historical practices for follow up of CRMS/CFSPID patients to help inform the development of Canadian consensus guidelines.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada.
- London Health Sciences Centre, Children's Hospital, London, Ontario, Canada.
- Arthur Labatt Family School of Nursing, Western University, London, Ontario, Canada.
ORCID-Profile: Dana Chemali, April Price
Förderung
- The authors received no specific funding for this work.
Zitieren
APA
Chemali, D., Fleischer, E., Uyeno, R., Mullowney, T., & Price, A. (2025). Variations in the Management of Canadian Patients With CFTR Related Metabolic Syndrome/Cystic Fibrosis Screen Positive, Inconclusive Diagnosis (CRMS/CFSPID). Pediatric Pulmonology. https://doi.org/10.1002/ppul.71200
Vancouver
Chemali D, Fleischer E, Uyeno R, Mullowney T, Price A. Variations in the Management of Canadian Patients With CFTR Related Metabolic Syndrome/Cystic Fibrosis Screen Positive, Inconclusive Diagnosis (CRMS/CFSPID). Pediatric Pulmonology. 2025. doi:10.1002/ppul.71200
BibTeX
@article{Chemali2025,
author = {Chemali, Dana and Fleischer, Erin and Uyeno, Ryan and Mullowney, Tara and Price, April},
title = {Variations in the Management of Canadian Patients With CFTR Related Metabolic Syndrome/Cystic Fibrosis Screen Positive, Inconclusive Diagnosis (CRMS/CFSPID)},
journal = {Pediatric Pulmonology},
year = {2025},
doi = {10.1002/ppul.71200}
}
EUVIMED